Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study

Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, V.N. Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William Blackwelder, Sai Prasad, Krishna Ella
doi: https://doi.org/10.1101/2021.12.28.21268468

Article usage

Article usage: December 2021 to November 2023

AbstractFullPdf
Dec 202144760514
Jan 202236051021222
Feb 2022125176207
Mar 202252421112
Apr 20222831179
May 20225071076
Jun 2022417339
Jul 2022154513
Aug 202288926
Sep 2022112117
Oct 2022103115
Nov 202263211
Dec 2022128410
Jan 202376722
Feb 20234558
Mar 20234917
Apr 202342715
May 202331314
Jun 20233064
Jul 20232218
Aug 202327107
Sep 202336918
Oct 20235038
Nov 20236447
Back to top
Posted December 29, 2021.
Download PDF
Data/Code
Email
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, V.N. Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William Blackwelder, Sai Prasad, Krishna Ella
medRxiv 2021.12.28.21268468; doi: https://doi.org/10.1101/2021.12.28.21268468
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area